Core Viewpoint - The inclusion of Fuhong Hanlin's drug, Fuzhuoning (Acalabrutinib), in the National Medical Insurance Drug List for 2025 signifies recognition of its clinical value and benefits for patients, enhancing accessibility for HR-positive, HER2-negative breast cancer patients and facilitating market promotion and sales strategies [1][2]. Group 1 - Fuzhuoning has been included in the National Medical Insurance Drug List under Category B, effective January 1, 2026, for use in combination with Fulvestrant for adult patients with HR-positive, HER2-negative recurrent or metastatic breast cancer who have progressed after endocrine therapy [1] - The drug was approved for marketing in China in May 2025, initially for the same indication, and received an additional indication in September 2025 for use in combination with aromatase inhibitors as initial endocrine therapy for adult patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer [1] Group 2 - The recognition by the National Medical Security Administration reflects the drug's clinical value, patient benefits, and innovation level, which will improve accessibility for patients and support the drug's market promotion and sales layout [2]
复宏汉霖(02696.HK)：复妥宁®(枸橼酸伏维西利胶囊)获纳入国家医保药品目录